New Article information at Drug Development Technology New and updated information from Article listed on www.drugdevelopment-technology.com http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ New Article information at Drug Development Technology http://www.drugdevelopment-technology.com/content/images/logo_big.gif Kisqali® (ribociclib) for the Treatment of HR+/HER2- Metastatic Breast Cancer http://www.drugdevelopment-technology.com/projects/kisqali-ribociclib-for-the-treatment-of-hrher2--metastatic-breast-cancer/ http://www.drugdevelopment-technology.com/projects/kisqali-ribociclib-for-the-treatment-of-hrher2--metastatic-breast-cancer/ Formerly known as LEE011, Kisqali® (ribociclib) is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor indicated for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer i… Wed, 15 Mar 2017 14:04:00 GMT Qtern (dapagliflozin and saxagliptin) for the Treatment of Type 2 Diabetes http://www.drugdevelopment-technology.com/projects/qtern-dapagliflozin-and-saxagliptin-for-the-treatment-of-type-2-diabetes/ http://www.drugdevelopment-technology.com/projects/qtern-dapagliflozin-and-saxagliptin-for-the-treatment-of-type-2-diabetes/ Qtern (dapagliflozin and saxagliptin) is a combination drug with sodium/glucose cotransporter (SGLT) 2 and dipeptidyl peptidase 4 (DPP-4) inhibitors indicated for the treatment of type 2 diabetes. Thu, 09 Mar 2017 00:00:00 GMT February's top stories: Merck's Phase III HIV-1 trial results, NIH's Phase I AGS-v vaccine trial http://www.drugdevelopment-technology.com/features/featurefebruarys-top-stories-mercks-phase-iii-hiv-1-trial-results-nihs-phase-i-ags-v-vaccine-trial-5757057/ http://www.drugdevelopment-technology.com/features/featurefebruarys-top-stories-mercks-phase-iii-hiv-1-trial-results-nihs-phase-i-ags-v-vaccine-trial-5757057/ Merck reported positive results from the Phase III trial of its non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine (MK-1439) for the treatment of patients with HIV-1 infection, and NIH's NIAID initiated a Phase I trial of vaccine AGS-v… Tue, 07 Mar 2017 00:00:00 GMT Alecensa (alectinib) for Treatment of ALK-positive Non-small Cell Lung Cancer http://www.drugdevelopment-technology.com/projects/alecensa-alectinib-for-treatment-of-alk-positive-non-small-cell-lung-cancer-nsclc/ http://www.drugdevelopment-technology.com/projects/alecensa-alectinib-for-treatment-of-alk-positive-non-small-cell-lung-cancer-nsclc/ Alecensa (alectinib) is a kinase inhibitor intended for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Thu, 02 Mar 2017 11:47:00 GMT Symbicort (budesonide and formoterol) for the Treatment of Asthma http://www.drugdevelopment-technology.com/projects/symbicort-budesonide-and-formoterol-for-the-treatment-of-asthma/ http://www.drugdevelopment-technology.com/projects/symbicort-budesonide-and-formoterol-for-the-treatment-of-asthma/ Symbicort (budesonide and formoterol) is an inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) indicated for the treatment of asthma in paediatric patients aged between six and 12 years. The drug was discovered and developed by AstraZe… Fri, 17 Feb 2017 00:00:00 GMT Emflaza (deflazacort) for the Treatment of Duchenne Muscular Dystrophy http://www.drugdevelopment-technology.com/projects/emflaza-deflazacort-for-the-treatment-of-duchenne-muscular-dystrophy/ http://www.drugdevelopment-technology.com/projects/emflaza-deflazacort-for-the-treatment-of-duchenne-muscular-dystrophy/ Emflaza™ (deflazacort) is the first glucocorticoid drug approved in the US for the treatment of patients aged five and older suffering from duchenne muscular dystrophy (DMD). The drug was discovered and developed by Marathon Pharmaceuticals. Fri, 17 Feb 2017 00:00:00 GMT Trulance™ (Plecanatide) for the Treatment of Adults with Chronic Idiopathic Constipation (CIC) http://www.drugdevelopment-technology.com/projects/trulance-plecanatide-for-the-treatment-of-adults-with-chronic-idiopathic-constipation-cic/ http://www.drugdevelopment-technology.com/projects/trulance-plecanatide-for-the-treatment-of-adults-with-chronic-idiopathic-constipation-cic/ Trulance™ (Plecanatide) is a guanylate cyclase-C (GC-C) agonist indicated for the treatment of adult patients with chronic idiopathic constipation (CIC). Mon, 06 Feb 2017 00:00:00 GMT January's top stories: TG Therapeutics' Phase II trial, antidepressant hip fracture risk http://www.drugdevelopment-technology.com/features/featurejanuarys-top-stories-tg-therapeutics-has-begun-its-phase-ii-investigator-and-calcimedica-has-initiated-the-phase-i-safety-studies-5731135/ http://www.drugdevelopment-technology.com/features/featurejanuarys-top-stories-tg-therapeutics-has-begun-its-phase-ii-investigator-and-calcimedica-has-initiated-the-phase-i-safety-studies-5731135/ TG Therapeutics began its Phase II investigator initiated trial of TGR-1202 in combination with ibrutinib to treat Diffuse Large B-cell Lymphoma (DLBCL), and a study suggested that antidepressant usage increases the risk of hip fracture. Drugdevelopm… Mon, 06 Feb 2017 00:00:00 GMT Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma http://www.drugdevelopment-technology.com/projects/avelumab-for-the-treatment-of-metastatic-merkel-cell-carcinoma/ http://www.drugdevelopment-technology.com/projects/avelumab-for-the-treatment-of-metastatic-merkel-cell-carcinoma/ Avelumab (formerly MSB0010718C) is a human PD-L1 monoclonal antibody being investigated for the treatment of metastatic Merkel cell carcinoma (MCC). Mon, 30 Jan 2017 00:00:00 GMT Spinraza (nusinersen) for the Treatment of Spinal Muscular Atrophy (SMA) http://www.drugdevelopment-technology.com/projects/spinraza-nusinersen-for-the-treatment-of-spinal-muscular-atrophy-sma/ http://www.drugdevelopment-technology.com/projects/spinraza-nusinersen-for-the-treatment-of-spinal-muscular-atrophy-sma/ Spinraza™ (nusinersen) is an anti-sense oligonucleotide indicated for treatment of spinal muscular atrophy (SMA) in paediatric and adult patients. Fri, 27 Jan 2017 00:00:00 GMT Rubraca (rucaparib) for the Treatment of Advanced Ovarian Cancer http://www.drugdevelopment-technology.com/projects/rubraca-rucaparib-for-the-treatment-of-advanced-ovarian-cancer/ http://www.drugdevelopment-technology.com/projects/rubraca-rucaparib-for-the-treatment-of-advanced-ovarian-cancer/ Poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor Rubraca™ (rucaparib) is indicated for the treatment of BRCA mutation-linked advanced ovarian cancer. Thu, 19 Jan 2017 00:00:00 GMT 2016: The year's biggest Drug Development Technology stories http://www.drugdevelopment-technology.com/features/feature2016-the-years-biggest-drug-development-technology-stories-5706284/ http://www.drugdevelopment-technology.com/features/feature2016-the-years-biggest-drug-development-technology-stories-5706284/ NIAID began a new HIV vaccine study in South Africa and Eli Lilly’s Phase III trial of Alzheimer disease drug failed. Drugdevelopment-technology wraps-up the key headlines from 2016. Tue, 03 Jan 2017 00:00:00 GMT Soliqua 100/33 for the Treatment of Type 2 Diabetes http://www.drugdevelopment-technology.com/projects/soliqua-10033-for-the-treatment-of-type-2-diabetes/ http://www.drugdevelopment-technology.com/projects/soliqua-10033-for-the-treatment-of-type-2-diabetes/ Developed by Sanofi, Soliqua 100/33 (insulin glargine & Lixisenatide injection) is indicated for the treatment of Type 2 diabetes. Mon, 19 Dec 2016 00:00:00 GMT November’s top stories: Wellcome’s clinical trial network, Eli Lilly’s Alzheimer disease drug trial http://www.drugdevelopment-technology.com/features/featurenovembers-top-stories-wellcomes-clinical-trial-network-eli-lillys-alzheimer-disease-drug-trial-5683416/ http://www.drugdevelopment-technology.com/features/featurenovembers-top-stories-wellcomes-clinical-trial-network-eli-lillys-alzheimer-disease-drug-trial-5683416/ UK’s Wellcome recommended a clinical trial network for efficient drug development, and Eli Lilly’s Alzheimer disease drug trial failed to meet endpoints. Drugdevelopment-technology.com wraps up the key headlines from November. Tue, 06 Dec 2016 00:00:00 GMT Xultophy 100/3.6 for the Treatment of Type 2 Diabetes http://www.drugdevelopment-technology.com/projects/xultophy-10036-for-the-treatment-of-type-2-diabetes/ http://www.drugdevelopment-technology.com/projects/xultophy-10036-for-the-treatment-of-type-2-diabetes/ Developed by Novo Nordisk, Xultophy 100/3.6 is indicated for the treatment of type 2 diabetes. Thu, 01 Dec 2016 00:00:00 GMT Stelara (Ustekinumab) for the Treatment of Moderate to Severe Crohn’s Disease http://www.drugdevelopment-technology.com/projects/stelara-ustekinumab-for-the-treatment-of-moderate-to-severe-crohns-disease/ http://www.drugdevelopment-technology.com/projects/stelara-ustekinumab-for-the-treatment-of-moderate-to-severe-crohns-disease/ Developed by Janssen Biotech, Stelara (Ustekinumab) is indicated for the treatment of moderate to severely active Crohn's disease. Tue, 29 Nov 2016 00:00:00 GMT Vemlidy (Tenofovir Alafenamide) for Treatment of Chronic Hepatitis B Virus Infection http://www.drugdevelopment-technology.com/projects/vemlidy-tenofovir-alafenamide-for-the-treatment-of-chronic-hepatitis-b-virus-infection/ http://www.drugdevelopment-technology.com/projects/vemlidy-tenofovir-alafenamide-for-the-treatment-of-chronic-hepatitis-b-virus-infection/ Developed by Gilead Sciences, Vemlidy (Tenofovir Alafenamide) is indicated for the treatment of Hepatitis B virus infection with compensated liver disease in adult patients. Thu, 24 Nov 2016 00:00:00 GMT Zinplava (bezlotoxumab) for the Treatment of Clostridium Difficile Infection http://www.drugdevelopment-technology.com/projects/zinplava-bezlotoxumab-for-the-treatment-of-clostridium-difficile-infection/ http://www.drugdevelopment-technology.com/projects/zinplava-bezlotoxumab-for-the-treatment-of-clostridium-difficile-infection/ Zinplava (bezlotoxumab) is an injectable solution developed by Merck indicated for the treatment of clostridium difficile infection (CDI) in adult patients who are already receiving anti-bacterial drug treatment. Tue, 22 Nov 2016 00:00:00 GMT Invokamet XR for the Treatment of Type 2 Diabetes in Adults http://www.drugdevelopment-technology.com/projects/invokamet-xr-for-the-treatment-of-type-2-diabetes-in-adults/ http://www.drugdevelopment-technology.com/projects/invokamet-xr-for-the-treatment-of-type-2-diabetes-in-adults/ Developed by Janssen Pharmaceuticals, Invokamet XR (Canagliflozin / Metformin Hydrochloride Extended Release) is indicated for the treatment of Type 2 diabetes in adults. Thu, 17 Nov 2016 00:00:00 GMT October’s top stories: Eurocine Vaccines initiated influenza vaccine study, IVF usage led to conceiving male child http://www.drugdevelopment-technology.com/features/featureoctobers-top-stories-eurocine-vaccines-influenza-vaccine-study-initiation-ivf-usage-leading-to-conceiving-male-child-5655728/ http://www.drugdevelopment-technology.com/features/featureoctobers-top-stories-eurocine-vaccines-influenza-vaccine-study-initiation-ivf-usage-leading-to-conceiving-male-child-5655728/ Eurocine Vaccines initiated a Phase I/II influenza vaccine study and a new study suggested in-vitro fertilisation increases the chances of conceiving a male child. Drugdevelopment-technology.com wraps up the key headlines from October 2016. Mon, 07 Nov 2016 00:00:00 GMT